MOLECULAR BASIS OF IMMUNOGLOBULIN HEAVY CHAIN SWITCH
Project Number5R01AI023283-08
Former Number2R01AI017558-04
Contact PI/Project LeaderSTAVNEZER, JANET M.
Awardee OrganizationUNIV OF MASSACHUSETTS MED SCH WORCESTER
Description
Abstract Text
The process of class switching, whereby B cells switch from production of
one class of immunoglobulin (Ig) to another, is highly regulated as
different classes are expressed in response to different antigens and at
different sites in the body. Ig class switching is effected by a DNA
recombination event which replaces the Cmu gene with one of the other
heavy chain constant region (CH) genes located 3' to the Cmu gene. How
the specificity of this event is controlled is unknown. However, it has
been shown that IgM+ cells capable of switching to specific antibody
classes have the corresponding unrearranged CH genes in an accessible or
active chromatic state, as demonstrated by the fact that these specific
CH genes are hypomethylated and are transcriptionally active.
We propose to continue our studies on the regulation of Ig class
switching using the mouse B cell lymphoma, I.29 IgM+ cells cloned from
this lymphoma can be induced to switch from expression of IgM to IgA or
less frequently to IgE or IgG2a, by treatment with LPS. This cell line
will be used to ask questions about how the class specificity is
controlled, especially focusing on the unction of transcription from the
germline Ig C alpha genes prior to heavy chain switching. We plan to
determine how certain T cell lymphokines which regulate switching
activate transcription of the germline alpha and epsilon genes. We also
propose to begin to identify cDNAs for genes which are induced in B cells
in the process of undergoing class switching. We will attempt to select
cDNAs that can cause switch recombination in a transfected plasmid.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
603847393
UEI
MQE2JHHJW9Q8
Project Start Date
01-August-1985
Project End Date
31-July-1994
Budget Start Date
01-August-1992
Budget End Date
31-July-1993
Project Funding Information for 1992
Total Funding
$276,705
Direct Costs
$177,717
Indirect Costs
$98,988
Year
Funding IC
FY Total Cost by IC
1992
National Institute of Allergy and Infectious Diseases
$276,705
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI023283-08
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI023283-08
Patents
No Patents information available for 5R01AI023283-08
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI023283-08
Clinical Studies
No Clinical Studies information available for 5R01AI023283-08
News and More
Related News Releases
No news release information available for 5R01AI023283-08
History
No Historical information available for 5R01AI023283-08
Similar Projects
No Similar Projects information available for 5R01AI023283-08